Study #2017-0913
A Study of Cancer related fatigue in patients with metastatic melanoma receiving Anti-PD1 Immunotherapy.
MD Anderson Study Status
Not Accepting
Treatment Agent
Methylphenidate
Description
This phase III trial studies how well methylphenidate and physical activity works in reducing cancer-related fatigue in patients who are receiving anti-PD1 immunotherapy for cancer that has spread to other places in the body. Central nervous systems stimulants, such as methylphenidate, may help to improve cognitive function. Physical activity uses techniques, such as aerobic and resistance exercises, which may help to improve quality of life. Giving methylphenidate and physical activity may help in reducing cancer-related fatigue in patients with metastatic cancer who receive anti-PD1 immunotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Study phase:
Phase III
Physician name:
Sriram Yennu
Department:
Palliative Care & Rehabilitation Medicine
For general questions about clinical trials:
1-866-230-7585
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.